Literature DB >> 9425905

Rapid cloning of expanded trinucleotide repeat sequences from genomic DNA.

M D Koob1, K A Benzow, T D Bird, J W Day, M L Moseley, L P Ranum.   

Abstract

Trinucleotide repeat expansions have been shown to cause a number of neurodegenerative diseases. A hallmark of most of these diseases is the presence of anticipation, a decrease in the age at onset in consecutive generations due to the tendency of the unstable trinucleotide repeat to lengthen when passed from one generation to the next. The involvement of trinucleotide repeat expansions in a number of other diseases--including familial spastic paraplegia, schizophrenia, bipolar affective disorder and spinocerebellar ataxia type 7 (SCA7; ref. 10)--is suggested both by the presence of anticipation and by repeat expansion detection (RED) analysis of genomic DNA samples. The involvement of trinucleotide expansions in these diseases, however, can be conclusively confirmed only by the isolation of the expansions present in these populations and detailed analysis to assess each expansion as a possible pathogenic mutation. We describe a novel procedure for quick isolation of expanded trinucleotide repeats and the corresponding flanking nucleotide sequence directly from small amounts of genomic DNA by a process of Repeat Analysis, Pooled Isolation and Detection of individual clones containing expanded trinucleotide repeats (RAPID cloning). We have used this technique to clone the pathogenic SCA7 CAG expansion from an archived DNA sample of an individual affected with ataxia and retinal degeneration.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9425905     DOI: 10.1038/ng0198-72

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  12 in total

Review 1.  Progress on the genetics of schizophrenia.

Authors:  A S Bassett
Journal:  J Psychiatry Neurosci       Date:  1998-11       Impact factor: 6.186

2.  Multivariate analysis of factors influencing repeat expansion detection.

Authors:  C Zander; J Thelaus; K Lindblad; M Karlsson; K Sjöberg; M Schalling
Journal:  Genome Res       Date:  1998-10       Impact factor: 9.043

3.  Mapping of a new autosomal dominant spinocerebellar ataxia to chromosome 22.

Authors:  L Zu; K P Figueroa; R Grewal; S M Pulst
Journal:  Am J Hum Genet       Date:  1999-02       Impact factor: 11.025

Review 4.  Studying polyglutamine diseases in Drosophila.

Authors:  Zhen Xu; Antonio Joel Tito; Yan-Ning Rui; Sheng Zhang
Journal:  Exp Neurol       Date:  2015-08-06       Impact factor: 5.330

5.  Characterization of intracellular aggregates using fluorescently-tagged polyglutamine-expanded androgen receptor.

Authors:  V Panet-Raymond; B Gottlieb; L K Beitel; H Schipper; M Timiansky; L Pinsky; M A Trifiro
Journal:  Neurotox Res       Date:  2001-07       Impact factor: 3.911

6.  Bidirectional expression of the SCA8 expansion mutation: one mutation, two genes.

Authors:  Yoshio Ikeda; Randy S Daughters; Laura P W Ranum
Journal:  Cerebellum       Date:  2008       Impact factor: 3.847

7.  Spinocerebellar ataxia 17 (SCA17) and Huntington's disease-like 4 (HDL4).

Authors:  Giovanni Stevanin; Alexis Brice
Journal:  Cerebellum       Date:  2008       Impact factor: 3.847

8.  Spinocerebellar ataxia type 8: molecular genetic comparisons and haplotype analysis of 37 families with ataxia.

Authors:  Yoshio Ikeda; Joline C Dalton; Melinda L Moseley; Kathy L Gardner; Thomas D Bird; Tetsuo Ashizawa; William K Seltzer; Massimo Pandolfo; Aubrey Milunsky; Nicholas T Potter; Mikio Shoji; John B Vincent; John W Day; Laura P W Ranum
Journal:  Am J Hum Genet       Date:  2004-05-19       Impact factor: 11.025

Review 9.  An update on Spino-cerebellar ataxias.

Authors:  Banashree Mondal; Pritikanta Paul; Madhuparna Paul; Hrishikesh Kumar
Journal:  Ann Indian Acad Neurol       Date:  2013-07       Impact factor: 1.383

10.  Genetic and molecular aspects of spinocerebellar ataxias.

Authors:  Viktor Honti; László Vécsei
Journal:  Neuropsychiatr Dis Treat       Date:  2005-06       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.